Revenue
Cost
Profit
| Item | Category | Value | YoY |
|---|---|---|---|
| Revenues | revenue | 4.71B | 5.22% |
| Other income (expense), net | revenue | 86.00M | 138.89% |
| Interest income | revenue | 9.00M | 80.00% |
| Operating income (loss) | profit | 93.00M | -75.72% |
| Total operating costs and expenses | cost | 4.62B | 12.77% |
| Aggregate | revenue | 188.00M | -51.42% |
| Cost of products sold | cost | 2.56B | -2.25% |
| Selling and administrative expense | cost | 1.21B | 8.59% |
| Integration, restructuring and transaction expense | cost | 533.00M | 473.12% |
| Research and development expense | cost | 249.00M | 7.33% |
| Other operating income (expense), net | revenue | 66.00M | 88.57% |
| Net (loss) income from continuing operations | profit | 37.00M | -76.58% |
| Income from continuing operations before income taxes | profit | 39.00M | -80.60% |
| Interest expense, nonoperating | cost | 149.00M | -0.67% |
| Income tax provision | cost | 76.00M | 76.74% |
| Segment | Value | YoY |
|---|---|---|
| Medical Essentials | 1.65B | 4.70% |
| Interventional | 1.36B | 7.36% |
| Connected Care | 1.12B | 4.87% |
| BioPharma Systems | 590.00M | 2.61% |
| Segment | Value | YoY |
|---|---|---|
| UNITED STATES | 2.92B | 5.08% |
| Non-US | 1.80B | 5.46% |
| Item | Category | Value | YoY |
|---|---|---|---|
| Finished products | assets | 2.16B | |
| Materials | assets | 801.00M | |
| Work in process | assets | 396.00M | |
| Inventories | assets | 3.36B | |
| Property, plant and equipment | assets | 13.55B | |
| Trade receivables, net | assets | 2.21B | |
| Prepaid expenses and other | assets | 1.43B | |
| Cash and equivalents | assets | 813.00M | |
| Restricted cash | assets | 202.00M | |
| Short-term investments | assets | 3.00M | |
| Total current assets | assets | 8.01B | |
| Less allowances for depreciation and amortization | assets | 7.47B | |
| Property, plant and equipment, net | assets | 6.08B | |
| Goodwill | assets | 25.95B | |
| Developed technology, net | assets | 5.89B | |
| Other assets | assets | 2.43B | |
| Customer relationships, net | assets | 2.00B | |
| Other intangibles, net | assets | 450.00M | |
| Total assets | assets | 50.83B | |
| Carrying value of long-term notes | liabilities | 14.71B | |
| Total current liabilities | liabilities | 8.51B | |
| Deferred income taxes and other liabilities | liabilities | 2.46B | |
| Long-term employee benefit obligations | liabilities | 1.03B | |
| Total shareholders’ equity | equity | 24.13B | |
| Treasury stock, value | equity | 11.66B | |
| Accumulated other comprehensive loss | equity | 1.76B | |
| Payables, accrued expenses and other current liabilities | liabilities | 5.93B | |
| Current debt obligations | liabilities | 2.57B | |
| Aggregate | equity | 37.56B | |
| Capital in excess of par value | equity | 19.77B | |
| Retained earnings | equity | 17.39B | |
| Common stock — $1 par value; authorized — 640,000,000 shares; issued — 370,594,401 shares in march 31, 2026 and september 30, 2025 | equity | 371.00M | |
| Deferred compensation | equity | 26.00M |
| Item | Value |
|---|---|
| Depreciation and amortization | 1.13B |
| Asset impairment charges | 450.00M |
| Net (loss) income from continuing operations | 274.00M |
| Share-based compensation | 149.00M |
| Pension obligation | -4.00M |
| Deferred income taxes | -44.00M |
| Other, net | -91.00M |
| Impacts of debt extinguishment | -122.00M |
| Adjustment to reconcile net income to cash provided by (used in) operating activity, increase (decrease) in operating capital | -417.00M |
| Item | Value |
|---|---|
| Payments for (proceeds from) investments | 23.00M |
| Payment for (proceeds from) other investing activity | -111.00M |
| Payments to acquire property, plant, and equipment | -233.00M |
| Item | Value |
|---|---|
| Distribution from spin-off entity, net (see note 2) | 3.86B |
| Change in short-term debt | 328.00M |
| Other, net | -63.00M |
| Payments of dividends | -589.00M |
| Payments of debt | -2.00B |
| Payments for repurchase of common stock | -2.25B |
| Item | Value |
|---|---|
| Cash and cash equivalents, beginning of period | 777.00M |
| Cash and cash equivalents, end of period | 1.01B |
Instantly decode complex 10-K and 10-Q data. Explore interactive Sankey diagrams for income and balance sheets, and intuitive waterfall charts for cash flows.
Search for a company and select a report on the left panel.
Request Stock Support